452 results on '"Ylikorkala, Olavi"'
Search Results
2. Increased risk for stress urinary incontinence in women with postmenopausal hormone therapy
3. Postmenopausal hormone therapy is accompanied by elevated risk for uterine prolapse
4. Vasomotor hot flashes and cardiac repolarization: a randomized placebo-controlled trial of postmenopausal hormone therapy
5. Primary fallopian tube carcinoma risk in users of postmenopausal hormone therapy in Finland
6. Effect of hot flushes on cardiovascular autonomic responsiveness: A randomized controlled trial on hormone therapy
7. Cardiovascular autonomic responsiveness in postmenopausal women with and without hot flushes
8. Use of estradiol–progestin therapy associates with increased risk for uterine sarcomas
9. Vaginal estradiol use and the risk for cardiovascular mortality
10. Postmenopausal hormone therapy–also use of estradiol plus levonorgestrel-intrauterine system is associated with an increased risk of primary fallopian tube carcinoma
11. Postmenopausal hot flushes and bone mineral density: a longitudinal study
12. Coronary Heart Disease Mortality and Hormone Therapy Before and After the Womenʼs Health Initiative
13. Soy–tibolone combination—Effect on lipids in postmenopausal monkeys and women
14. Equol production capability is associated with favorable vascular function in postmenopausal women using tibolone; no effect with soy supplementation
15. Effect of various forms of postmenopausal hormone therapy on the risk of ovarian cancer—A population-based case control study from Finland
16. Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women
17. Effect of oral and transdermal hormone therapy on hyaluronic acid in women with and without a history of intrahepatic cholestasis of pregnancy
18. Benefits and risks of long-term low-dose oral continuous combined hormone therapy
19. Adiponectin Concentrations in Maternal Serum: Elevated in Preeclampsia But Unrelated to Insulin Sensitivity
20. Smoking is accompanied by a suppressed cervical nitric oxide release in women with high-risk human papillomavirus infection
21. Decreasing perinatal mortality in placental abruption
22. Susceptibility loci for preeclampsia on chromosomes 2p25 and 9p13 in finnish families. (Report)
23. Postmenopausal estradiol–progestagen therapy and risk for uterine cervical cancer
24. A Nationwide Cohort Study on the Incidence of Meningioma in Women Using Postmenopausal Hormone Therapy in Finland
25. Cervical nitric oxide release in Chlamydia trachomatis and high-risk human papillomavirus infection
26. Cervical nitric oxide release and persistence of high-risk human papillomavirus in women
27. Endometrial cancer associated with various forms of postmenopausal hormone therapy: A case control study
28. Self-reported smoking habits and serum cotinine levels in women with placental abruption
29. Endometriosis and assisted reproduction techniques
30. Do the dose or route of administration of norethisterone acetate as a part of hormone therapy play a role in risk of breast cancer: National-wide case-control study from Finland
31. Male fetal sex is associated with earlier onset of placental abruption
32. A case-control study on hormone therapy as a risk factor for breast cancer in Finland: Intrauterine system carries a risk as well
33. Maternal Serum Angiopoietin-1 and -2 and Tie-2 in Early Pregnancy Ending in Preeclampsia or Intrauterine Growth Retardation
34. Effect of Hot Flushes on Vascular Function: A Randomized Controlled Trial
35. Maternal deaths in Finland: Focus on placental abruption
36. Maternal serum endostatin at gestational weeks 16–20 is elevated in subsequent pre-eclampsia but not in intrauterine growth retardation
37. Abnormal cervical cytology is associated with increased nitric oxide release in the uterine cervix
38. Lack of effect of isoflavonoids on the vagina and endometrium in postmenopausal women
39. Misoprostol induces cervical nitric oxide release in pregnant, but not in nonpregnant, women
40. Culturing of human vascular endothelial cells strongly affects their endothelin-1 and prostacyclin production
41. Failure of second-trimester measurement of soluble endoglin and other angiogenic factors to predict placental abruption
42. Elevated maternal second-trimester serum alpha-fetoprotein as a risk factor for placental abruption
43. Maternal origin of nucleated erythrocytes in peripheral venous blood of pregnant women
44. Mifepristone-induced nitric oxide release and expression of nitric oxide synthases in the human cervix during early pregnancy
45. Clinical presentation and risk factors of placental abruption
46. Maternal Serum-Soluble Vascular Endothelial Growth Factor Receptor-1 in Early Pregnancy Ending in Preeclampsia or Intrauterine Growth Retardation
47. Prepregnancy risk factors for placental abruption
48. Is there any link between insulin resistance and inflammation in established preeclampsia?
49. Effect of antiprogesterone mifepristone followed by misoprostol on circulating leptin in early pregnancy
50. Changes in bone mineral density during and after 3 years’ use of tamoxifen or toremifene
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.